#HVO hVIVO PLC – HCT contract signed with ILiAD Biotechnologies April 22, 2026 – Posted in: hVIVO (HVO)

· World’s first pivotal Phase III human challenge trial (“HCT”) in Bordetella pertussis (the bacteria that causes whooping cough) for ILiAD Biotechnologies vaccine candidate, BPZE1 · hVIVO’s largest HCT to date, with over 500 participants anticipated, with revenue recognition expected from H1 2026 · Trial expected to be hVIVO’s largest value HCT to date; making a strong contribution to near and mid‑term revenues with the majority expected to be recognised during 2026 and 2027 London, UK – 22 April 2026, hVIVO plc (AIM: HVO), a purpose-built,…

#HVO hVIVO PLC – LOI signed for Phase 3 Whooping Cough trial January 27, 2025 – Posted in: hVIVO (HVO)

Highlights · hVIVO has been selected to conduct a large-scale Phase 3 human challenge trial (“HCT”) for ILiAD Biotechnologies’ lead Bordetella pertussis (whooping cough) vaccine candidate, BPZE1 · World’s first pivotal Phase 3 human challenge trial in Bordetella pertussis · Expanding hVIVO’s human challenge model portfolio · Expected to be Company’s largest HCT to date · Trial expected to commence H2 2025 hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world…

#HVO hVIVO PLC – HCT contract signed with ILiAD Biotechnologies April 22, 2026 – Posted in: hVIVO (HVO)

#HVO hVIVO PLC – LOI signed for Phase 3 Whooping Cough trial January 27, 2025 – Posted in: hVIVO (HVO)

Address

Contact

Social

LEGAL